Researchers at Baylor College of Medicine have identified a new genetic vulnerability in acute myeloid leukemia, or AML. This discovery offers a potential path toward more effective treatments that spare healthy cells from the damage often caused by standard cancer therapies. The team focused on how drugs that neutralize mutations of the enzyme FLT3 function within the body.
While FLT3 mutations are common drivers of AML, many patients eventually develop resistance to current inhibitors. The research team explored an alternative mechanism for how these drugs induce cancer cell death. By studying patient-derived samples and laboratory models, they found that FLT3 inhibitors trigger a process known as ferroptosis. This mechanism causes oxygen to damage lipids within the cells, which ultimately leads to cell death.
Further investigation revealed that mutant FLT3 proteins activate a specific protein called GPX4. This protein acts as a defense system, preventing ferroptosis in cancer cells. When FLT3 inhibitors are administered, they block the production of selenoproteins, including GPX4. Without this protective protein, the cancer cells become unable to prevent lipid peroxidation and succumb to the treatment.
The study also suggests a practical concern for patients undergoing these treatments. The researchers found that dietary vitamin E, which naturally prevents ferroptosis, can reduce the effectiveness of the drug gilteritinib. Patients and their medical teams should be aware of this potential interaction when managing therapy. This identification of the ferroptosis pathway provides a clearer target for future drug development in the fight against AML.